Intelligence for the Dealmaking Community since 1965
Intelligence for the Dealmaking Community since 1965
After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.
This is premium content

To read the full story, please upgrade your plan.

Upgrade plan
Login to your account

Eye conditions

image
Healthcare
Astellas Pharma Buys Iveric Bio for $5.9B
Iveric is developing a drug to treat geographic atrophy, a condition that leads to the loss of retinal tissue in the eye. 
May 1, 2023

Trending

1.
Inside Deal Origination Today: More Competitive, More Data-Driven — and Still Relationship-Led
May 18, 2026
2.
KKR Opens Milan Office
May 28, 2026
3.
The New Battle for the Lower Middle Market: How to Win Over Owners Who Don’t Want to Sell
May 21, 2026
4.
Secondaries Edge: Firms Investing in CVs Are Starting to Look Like the Firms Launching Them
May 27, 2026
5.
Middle-Market Pro Sports Ecosystem Deals Are Gearing Up, Bankers Say
May 19, 2026
6.
Why Healthcare PE Is Racing Into AI
May 22, 2026
7.
Hilco Global Appoints Shana Thomas as Chief Compliance Officer
May 21, 2026
8.
Secondaries Edge: Secondaries Boom Faces Quality Squeeze as New Liquidity Machines Multiply
June 10, 2026
9.
Military, Aerospace and Reshoring Fuel Middle Market M&A and Capital-Raising
May 14, 2026